Page last updated: 2024-12-10

ly 163892

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5284585
CHEMBL ID1013
CHEBI ID47544
SCHEMBL ID34153
MeSH IDM0154872

Synonyms (46)

Synonym
loracarbefum
BIDD:GT0753
(6r,7s)-7-{[(2r)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
7beta-[(2r)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid
76470-66-1
loracabef
loracarbef
DB00447
loracarbef, anhydrous
loracarbef anhydrous
anhydrous loracarbef
loracarbefum [inn-latin]
ly163892
1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r-(6alpha,7beta(r*)))-
1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2r)-aminophenylacetyl)amino)-3-chloro-8-oxo-, (6r,7s)-
kt 3777
ly 163892
CHEMBL1013
chebi:47544 ,
D08143
loracarbef (inn)
lorbef (tn)
(6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
loracarbef [usan:inn:ban]
unii-w72i5zt78z
w72i5zt78z ,
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-, (6r,7s)-
lorbef
loracarbef [inn]
loracarbef [who-dd]
loracarbef [mi]
AKOS015895936
BRD-K28935038-001-01-4
JAPHQRWPEGVNBT-UTUOFQBUSA-N
CCG-220611
SCHEMBL34153
DTXSID7023223
(6r,7s)-7-[(2r)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
HMS3713L04
Q979521
kt 3777; ly 163892; lorabid
gtpl12247
CS-0013651
NCGC00510749-15
HY-B1682
EN300-26524873

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Nevertheless, treatment with loracarbef resulted in the lowest rate of discontinuation of therapy due to drug-related adverse events."( Efficacy and safety of loracarbef in the treatment of pneumonia.
Hyslop, DL, 1992
)
0.28
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination half-life ranged from 70."( Pharmacokinetics of loracarbef and interaction with acetylcysteine.
Boeckh, M; Deppermann, KM; Koeppe, P; Lode, H; Roller, S; Stelzer, I, 1992
)
0.28
" In patients with streptococcal pharyngitis, the mean maximum serum concentration (Cmax), the time to achieve maximum concentration (Tmax), area under the serum concentration-time curve (AUC) and elimination half-life (t1/2) were 10."( Pharmacokinetics of loracarbef in pediatric patients.
Koranyi, KI; Nahata, MC,
)
0.13
" In adults, the Cmax following administration of the suspension or solution formulations is higher than that achieved following administration of the capsule formulation, and the time to reach peak concentration (Tmax) is increased when loracarbef is administered as a capsule; however, the area under the curve, plasma half-life, and percentage of oral dose excreted in the urine are comparable among all formulations."( Pharmacokinetic profile of loracarbef.
DeSante, KA; Zeckel, ML, 1992
)
0.28
"The pharmacokinetic disposition of 200- and 400-mg doses of a novel carbacephem, loracarbef, was determined over a dose interval on day 8, after ingestion of drug doses twice daily for 7 days, in 20 young, healthy volunteers of both genders."( Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state.
Aoki, FY; Hoban, DJ; Sitar, DS, 1994
)
0.29
" Single-dose studies have demonstrated considerable pharmacokinetic differences among these compounds."( Pharmacokinetics of new oral cephalosporins, including a new carbacephem.
Borner, K; Fassbender, M; Koeppe, P; Lode, H; Schaberg, T, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" The substance was well absorbed with a mean peak level of 19."( Pharmacokinetics of loracarbef and interaction with acetylcysteine.
Boeckh, M; Deppermann, KM; Koeppe, P; Lode, H; Roller, S; Stelzer, I, 1992
)
0.28
" These data are consistent with complete bioavailability for an oral beta-lactam antibiotic drug that is virtually completely eliminated unchanged by the kidney."( Pharmacokinetic disposition of loracarbef in healthy young men and women at steady state.
Aoki, FY; Hoban, DJ; Sitar, DS, 1994
)
0.29
" The drug is well absorbed after oral administration and plasma concentrations achieved in patients are greater than the in vitro minimum inhibitory concentrations for most of the above bacteria."( Loracarbef: a new orally administered carbacephem antibiotic.
Force, RW; Nahata, MC, 1993
)
0.29
" Pharmacokinetic studies in the elderly and in children indicate that the bioavailability of these agents is not influenced by age."( Pharmacokinetics of new oral cephalosporins, including a new carbacephem.
Borner, K; Fassbender, M; Koeppe, P; Lode, H; Schaberg, T, 1993
)
0.29
" Three clinically evaluated orally absorbed carbacephems were taken up by Caco-2 cells, consistent with their excellent bioavailability in humans."( Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells.
Berry, DM; Dantzig, AH; Duckworth, DC; Snyder, NJ; Spry, DO; Tabas, LB, 1997
)
0.3
"This randomized open-label single-dose crossover pharmacokinetic study was carried out to assess the effect of different diets on the bioavailability of loracarbef in 24 healthy male volunteers."( The effect of four different types of diet on the bioavailability of loracarbef.
Ahmed, T; Bapujee, AT; Monif, T; Saha, N; Sharma, PL; Singh, T,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Nearly 60% of the dose was excreted unchanged in the urine during the dosage interval."( Pharmacokinetics of loracarbef in pediatric patients.
Koranyi, KI; Nahata, MC,
)
0.13
" Because loracarbef is eliminated primarily by the kidney, dosage must be reduced in patients with moderate-to-severe renal insufficiency."( Pharmacokinetic profile of loracarbef.
DeSante, KA; Zeckel, ML, 1992
)
0.28
"73 m2), the dose should be halved or the dosing interval doubled; patients with severe renal insufficiency who are not receiving dialysis should be treated with the normal dose given once every 3 to 5 days."( Effects of renal dysfunction on the pharmacokinetics of loracarbef.
Cerimele, BJ; Davidson, RL; DeSante, KA; Farlow, DS; Hatcher, BL; Quadracci, LJ; Therasse, DG, 1993
)
0.29
"These seven agents offer wider choices in drug regimens, and the use of certain agents should improve patient compliance because of less frequent dosing and shorter duration of treatment."( New antibacterial agents.
Hussar, DA, 1993
)
0.29
" Potential advantages of the new carbacephem may be improved patient compliance with its less frequent dosing schedule (once or twice a day, depending on the infection), and a low incidence of adverse effects."( Loracarbef: a new orally administered carbacephem antibiotic.
Force, RW; Nahata, MC, 1993
)
0.29
" Simulated pediatric dosage regimens and target peak concentrations in the central compartment were as follows: penicillin V-potassium, 26 mg/kg of body weight every 6 h (q6h) and 14 micrograms/ml; cefaclor, 13."( Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Cappelletty, DM; Rybak, MJ, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
carbacephemAny member of a group of synthetic antibiotics, similar to cephems but with carbon substituted for the sulfur; all possessing an acylated amine functionality at C-6 and (S,R) stereochemistry at C-6 and C-7.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
carbacephemAny member of a group of synthetic antibiotics, similar to cephems but with carbon substituted for the sulfur; all possessing an acylated amine functionality at C-6 and (S,R) stereochemistry at C-6 and C-7.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.16230.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1577966Antimicrobial activity against Enterococcus faecium NCTC after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID269449Antibacterial activity against TEM1 beta-lactamase Escherichia coli IV-3-2 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID209734Minimum inhibitory concentration was measured against streptococcus pneumonia PARK1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID26413Half-life is evaluated1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID269448Antibacterial activity against wild type Escherichia coli DC0 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID739979Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID269455Antibacterial activity against Klebsiella pneumoniae ATCC 8308 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID162760In vitro inhibitory activity against Pseudomonas aeruginosa X2581990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID38399Binding affinity towards AmpC beta-lactamase binding site from Escherichia coli; NA means not applicable2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-based approach for binding site identification on AmpC beta-lactamase.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID269444Antibacterial activity against wild type Staphylococcus aureus SG 511 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID739985Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID269454Antibacterial activity against Salmonella enterica ATCC 13311 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1577972Antimicrobial activity against Escherichia coli ATCC 25922 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID205900Minimum inhibitory concentration was measured against staphylococcus epidermidis 2221991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID739982Antibacterial activity against Enterococcus faecium NCTC 7171 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID269453Antibacterial activity against Escherichia coli ATCC 33475 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID65040Minimum inhibitory concentration was measured against Escherichia coli EC141991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID1577969Antimicrobial activity against Acinetobacter baumannii ATCC 17961 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID680867TP_TRANSPORTER: inhibition of Cefadroxil uptake (apical pH 5.5, Cefadroxil: 1000 uM, Loracarbef: 10000 uM) in Caco-2 cells1996The Journal of pharmacology and experimental therapeutics, May, Volume: 277, Issue:2
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
AID16865Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID269447Antibacterial activity against wild type Mycobacterium vaccae IMET10670 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID200346Minimum inhibitory concentration was measured against salmonella 11351991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID1577970Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID1577968Antimicrobial activity against Klebsiella pneumoniae 700603 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID200347Minimum inhibitory concentration was measured against salmonella X5141991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID739981Antibacterial activity against Staphylococcus aureus SG 511 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID163047In vitro inhibitory activity against Proteus rettgeri C241990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID209615In vitro inhibitory activity against Streptococcus pyogenes Park1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID739983Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID269452Antibacterial activity against Escherichia coli X580 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID739980Antibacterial activity against Enterobacter aerogenes ATCC 35029 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID164052Minimum inhibitory concentration was measured against Pseudomonas X5281991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and siderophore and antibacterial activity of N5-acetyl-N5-hydroxy-L-ornithine-derived siderophore-beta-lactam conjugates: iron-transport-mediated drug delivery.
AID680864TP_TRANSPORTER: inhibition of Cefadroxil uptake (apical pH 6.5, Cefadroxil: 1000 uM, Loracarbef: 10000 uM) in Caco-2 cells1996The Journal of pharmacology and experimental therapeutics, May, Volume: 277, Issue:2
Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1577971Antimicrobial activity against Enterobacter aerogenes ATCC 35029 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID678883TP_TRANSPORTER: inhibition of Cefadroxil uptake (Cefadroxil: 25 uM, Loracarbef: 5000uM) in Xenopus laevis oocytes1996Proceedings of the National Academy of Sciences of the United States of America, Jan-09, Volume: 93, Issue:1
Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter.
AID68697In vitro inhibitory activity against Escherichia coli EC141990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID269446Antibacterial activity against VRE Enterococcus faecalis 1528 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID739984Antibacterial activity against Acinetobacter baumannii ATCC 17961 after 18 hrs by broth microdilution method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID95890In vitro inhibitory activity against Klebsiella X261990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID207057In vitro inhibitory activity against Staphylococcus aureus X1.11990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID68344In vitro inhibitory activity against Enterobacter cloacae EB51990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID1577967Antimicrobial activity against Staphylococcus aureus SG 511 after 18 hrs by CLSI protocol based broth microdilution method2019European journal of medicinal chemistry, Nov-15, Volume: 182An overview of recent progress in siderophore-antibiotic conjugates.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID269450Antibacterial activity against ampC beta-lactamase Enterobacter cloacae P99 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID85799In vitro inhibitory activity against Haemophilus influenza C.L1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.
AID269445Antibacterial activity against MRSA Staphylococcus aureus 134/93 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID269451Antibacterial activity against PSE1 beta-lactamase Pseudomonas aeruginosa IV-3-13 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID269456Antifungal activity against Candida albicans BMSY 212 by agar diffusion assay2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
The synthesis and in vitro testing of structurally novel antibiotics derived from acylnitroso Diels-Alder adducts.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (122)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (10.66)18.7374
1990's85 (69.67)18.2507
2000's11 (9.02)29.6817
2010's12 (9.84)24.3611
2020's1 (0.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.91 (24.57)
Research Supply Index5.16 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (26.09%)5.53%
Reviews20 (14.49%)6.00%
Case Studies4 (2.90%)4.05%
Observational0 (0.00%)0.25%
Other78 (56.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]